8TH ANNUAL NEUROSCIENCE INNOVATION FORUM

12TH JANUARY 2025 | MARINES' MEMORIAL CLUB | SAN FRANCISCO | USA ​ ABOUT THE #Sachs_NIF FORUM We are pleased to announce that the 8th Annual Neuroscience Innovation Forum (#Sachs_NIF) will take place once again at the Marines’ Memorial Club, San Francisco on the 12th of January 2025, a day before the JP Morgan meeting and the Virtual Week will take place the week after, from the 21st - 23rd of January. In addition, building on the success of previous obesity panels and keynote in our Swiss events, we are pleased to introduce the 1st Annual BioPharma Obesity Innovation Forum (#Sachs_BOIF), which will take place a day before, on the 11th of January, offering relevant attendees the opportunity to register for both events. Positioned at the beginning of JPM week, the NIF forum focuses on the latest developments across key areas of neuroscience, which are currently attracting record investor interest and deal flow. The main programme for the 8th Annual NIF will feature more than... Read more

12TH JANUARY 2025 | MARINES' MEMORIAL CLUB | SAN FRANCISCO | USA ​ ABOUT THE #Sachs_NIF FORUM We are pleased to announce that the 8th Annual Neuroscience Innovation Forum (#Sachs_NIF) will take place once again at the Marines’ Memorial Club, San Francisco on the 12th of January 2025, a day before the JP Morgan meeting and the Virtual Week will take place the week after, from the 21st - 23rd of January. In addition, building on the success of previous obesity panels and keynote in our Swiss events, we are pleased to introduce the 1st Annual BioPharma Obesity Innovation Forum (#Sachs_BOIF), which will take place a day before, on the 11th of January, offering relevant attendees the opportunity to register for both events. Positioned at the beginning of JPM week, the NIF forum focuses on the latest developments across key areas of neuroscience, which are currently attracting record investor interest and deal flow. The main programme for the 8th Annual NIF will feature more than 8 hours of high-level keynotes and panel discussions addressing the important advances in therapeutic, neurotech, and diagnostics fields. Industry leaders will address the following topics: Sunday, 12th of January: Dealmakers Roundtable: Challenges & Opportunities in a Strong Market Innovation in AD/PD & Other Cognitive Disorders Panel Keynote Speech NextGen Modalities for Rare & Orphan Neurological Diseases Panel Keynote Speech: "Transforming Rare Neurological Trials: Digital Twins Enhance Precision & Reduce Placebos” Revolutionizing Neuropsychiatric Treatments: Novel Approaches Panel Future of Psychedelics Panel Neurotech Innovation Panel Investor Roundtable In-Person Meetings - 12th of January  Virtual Meetings via Online Meeting System - 21st - 23rd of January  Networking Reception - 12th of January The target audience consists of buy and sell-side analysts from investment banks and funds, alongside partnering executives from pharma, biotech, medtech, neurotech, and diagnostics companies. We anticipate over 300 delegates in-person and 30+ company presentations by established and emerging companies. This will include a limited number of live presentations taking place in dedicated presentation tracks, alongside virtual company showcases, which will be available on demand. Recorded sessions will also be added on demand on the event portal during the virtual week.     The In-Person meetings will be taking place on the 12th of January, while virtual meetings will take place on the 21st - 23rd of January. For the virtual meetings, the system will allow you to have a secure audio/video call, as well as the option to present slides using a screen share function and we will have a dedicated room for in-person meetings. The conference will be held in the Pacific Standard Time (PST) zone.    The physical programme will consist of the usual panels and keynotes, which will be available on demand for the virtual audience, the week after JP Morgan meeting. Additionally, there will be pre-arranged in-person meetings, live and on demand company showcases , and a reception. The in-person event will be followed by an additional week of virtual meetings available through the audio/video online meeting system, starting from the 21st of January. Confirmed Keynote Speakers Include: Andrew Stelzer, Head of Business Development, Unlearn.AI, Inc. Jonathan Javitt, Founder & Chief Scientist, NRx Pharmaceuticals, Inc. Confirmed Speakers & Chairs Include: Alexander Gebauer, Co-Founder & Executive Chairman, Galimedix Therapeutics, Inc. Bruce Leuchter, President & CEO, Neurvati Neurosciences, Inc. Carla Lema Tomé, Executive Director of Business Development, Otsuka Pharmaceutical Co., Ltd. Carlos Buesa, Founder & CEO, Oryzon Genomics, S.A. Céline Bouquet, Neuroscience, Ophthalmology & Rare Diseases Pharma Partnering Site Head Basel, F. Hoffmann-La Roche Ltd. Christian Howell, CEO, Cognito Therapeutics, Inc. Christopher Reyes, CEO, Bloom Science, Inc. Cornelia Jahnel, Managing Partner, GOLDTRACK Ventures GmbH Daniel Lee, Managing Director, PJT Partners Diana Saraceni, Co-Founder & General Partner, Panakès Partners SGR SpA Dmitrij Hristodorov, General Partner, Forbion Doug Drysdale, CEO, Cybin Inc. Edouard Caram, Sr. Director, Global Partnership Rare Diseases & Neurosciences, Ipsen Eliseo Salinas, Head of R&D, Delix Therapeutics, Inc. Erwin Böttinger, CEO, Wyss Center for Bio and Neuroengineering Fabio De Luca, Executive VP Corporate Development, Angelini Pharma S.p.A. Gaia Skibinski, Director of Discovery & Translational Research, The Michael J. Fox Foundation for Parkinson's Research Ginger Johnson, President, BioConsulting, Lumanity Greg Mayes, President & CEO, Reunion Neuroscience, Inc. Gregor Macdonald, VP, Head of BD & Licensing, Search & Assessment, H. Lundbeck A/S Ilise Lombardo, CEO, Noema Pharma AG James Cavuoto, Editor, Neurotech Reports Jay Olson, Managing Director & Senior Analyst, Oppenheimer & Co. Inc. Jeffrey Cohen, Managing Director, Equity Research, Healthcare & Medical Technologies, Ladenburg Thalmann & Co. Inc. Jenny Laird, VP, Search & Evaluation Neuroscience, Eli Lilly and Company Jens Wendland, Chief Medical Officer, Kynexis Therapeutics Joel Sandler, Associate Partner, Ipsos Healthcare Advisory Service Jon Walsh, Founder & VP of Technology, Unlearn.AI, Inc. Joseph Tucker, CEO, Enveric Biosciences, Inc. Julie Rachline, CEO, BrainTale Kabir Nath, CEO, Compass Pathways Ken Mariash, CEO, Sinaptica Therapeutics, Inc. Kuldeep Neote, Entrepreneur In Residence, National Institute on Aging (NIA) Laszlo Kiss, CBO & Head of Research, Gilgamesh Pharmaceuticals Lisa Ricciardi, President & CEO, Cognition Therapeutics, Inc. Mankit Law, Senior Director, BD, Search & Evaluation, GSK Manuel López-Figueroa, Scientific Liaison, Pritzker Neuropsychiatric Disorders Research Consortium Murali Gopalakrishnan, Global Head, Neuroscience Search & Evaluation, Corporate Business & Strategy Office, AbbVie, Inc. Paolo Di Giorgio, Managing Director & CEO, Angelini Ventures S.p.A. Robert Barrow, CEO, MindMed Sahil Kirpekar, CBO, atai Life Sciences N.V. Sander van Deventer, CEO, VectorY Tx Seth Lederman, Chairman & CEO, Tonix Pharmaceuticals Holding Corp. Shaheen Lakhan, Chief Medical Officer, Click Therapeutics, Inc. Steve Dickman, CEO, CBT Advisors Sumant Kulkarni, Managing Director, Biotechnology Equity Research, Canaccord Genuity LLC Thomas Shrader, Managing Director & Healthcare Analyst, BTIG, LLC Tim Luker, VP, Lilly Ventures, Eli Lilly and Company Vikram Sudarsan, President & CEO, Engrail Therapeutics, Inc. More TBA...